Abbott shares attractive following spin-off, says Wells Fargo After Abbott spun off its proprietary pharmaceuticals business, Wells Fargo believes the new Abbott's stock is attractive, partly due to what the firm sees as the company's above-average top- and bottom-line growth outlook and significant margin expansion opportunities. The firm lowered its valuation range for the stock to $33-$34 from $71-$74 to reflect the spin-off, and maintains an Outperform rating on the shares.
News For ABT From The Last 14 Days
Check below for free stories on ABT the last two weeks.
Subscribe for More Information